LongeVC

LongeVC invests in early-stage companies applying biotechnology, artificial intelligence, and decentralized science to extend healthy human lifespan. The firm specifically targets projects where blockchain or token-based mechanisms can improve research funding, IP ownership, or clinical data coordination — areas it considers underserved by both traditional biotech venture and generalist crypto funds. The thesis rests on the view that longevity research is undercapitalized relative to its potential impact and that decentralized capital formation can close that gap.

The firm invests through both equity and token positions, often within the same company. LongeVC uses a Token-for-Equity model in which it acquires equity in a biotech startup while simultaneously helping the company design and launch token-based research funding mechanisms. The fund also makes direct liquid token investments and participates in early-stage equity rounds, giving it exposure to both traditional venture returns and digital-asset upside.

Founding Partners Sergey Jakimov and Garry Zmudze, alongside Managing Partner Ilya Suharenko, lead the firm's investment decisions. The partnership brings combined expertise in computational biology, distributed-systems engineering, and venture capital. The firm has not publicly detailed an investment committee structure beyond the named partners.

LongeVC sources deals through deep engagement with decentralized science communities, longevity research networks, and blockchain developer ecosystems — channels that generalist healthcare funds rarely access. The firm's presence in both US biotech hubs and European research centers, combined with its partners' technical credibility in Web3-native circles, gives it visibility into projects before they reach broader venture attention. Specific sourcing mechanisms — whether proprietary events, advisor networks, or inbound from portfolio company referrals — have not been publicly detailed.

LongeVC's founders are associated with the Longevity Science Foundation, a Swiss-based nonprofit that funds aging research, but the two entities are structurally separate. The foundation operates as a grant-making and research-funding organization, while LongeVC is a for-profit venture firm. Overlap in leadership and thematic focus creates a research pipeline that can inform investment decisions, but the foundation does not invest in portfolio companies and LongeVC does not direct the foundation's grant allocation.